Brain monoamine systems in multiple system atrophy: A positron emission tomography study

Neurobiology of Disease

Volumn 46, Issue 1, 2012, Pages 130-136

  Lewis, Stephanie J ^a   Pavese, Nicola ^a   Rivero Bosch, Maria ^a   Eggert, Karla ^b   Oertel, Wolfgang ^b   Mathias, Christopher J ^a,c   Brooks, David J ^a   Gerhard, Alex ^d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

18F dopa; Extrastriatal; Monoamine; Multiple system atrophy (MSA); Parkinson's disease; Positron emission tomography (PET)

Indexed keywords

6 FLUORODOPA F 18; BRAIN MONOAMINE; DOPAMINE; NORADRENALIN; SEROTONIN;

ADULT; ARTICLE; AUTONOMIC INNERVATION; BRAIN DYSFUNCTION; BRAIN MAPPING; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE DURATION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC TRANSMISSION; EXTRASTRIATE BODY AREA; FEMALE; GLOBUS PALLIDUS; HUMAN; IDIOPATHIC DISEASE; IN VIVO STUDY; LOCUS CERULEUS; MALE; MICROMORPHOLOGY; MONOAMINERGIC SYSTEM; NEUROIMAGING; NORADRENALIN BRAIN LEVEL; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PUTAMEN; RED NUCLEUS; SENSITIVITY AND SPECIFICITY; SEROTONIN BRAIN LEVEL; SEROTONINERGIC TRANSMISSION; SHY DRAGER SYNDROME; STRIATE CORTEX;

AGED; BIOGENIC MONOAMINES; BRAIN; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NOREPINEPHRINE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN;

EID: 84858153834     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.053     Document Type: Article

References (37)

1. Antonini A., Leenders K.L., Vontobel P., et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997, 120:2187-2195.
2. Benarroch E.E., Schmeichel A.M., Parisi J.E. Depletion of mesopontine cholinergic and sparing of raphe neurons in multiple system atrophy. Neurology 2002, 59:944-946.
3. Benarroch E.E., Schmeichel A.M., Low P.A., Parisi J.E. Involvement of medullary serotonergic groups in multiple system atrophy. Ann. Neurol. 2004, 55:418-422.
4. Benarroch E.E., Smithson I.L., Low P.A., Parisi J.E. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure. Ann. Neurol. 2007, 43:156-163.
5. Benarroch E.E., Schmeichel A.M., Sandroni P., Parisi J.E., Low P. Rostral raphe involvement in Lewy body dementia and multiple system atrophy. Acta Neuropathol. 2007, 114:213-220.
6. Benarroch E.E., Schmeichel A.M., Low P.A., Sandroni P., Parisi J.E. Loss of A5 noradrenergic neurons in multiple system atrophy. Acta Neuropathol. 2008, 115:629-634.
7. Benrud-Larson L.M., Sandroni P., Schrag A., Low P.A. Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov. Disord. 2005, 20:951-957.
8. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol. 1990, 28:547-555.
9. Fahn S., Elton R.L. Unified Parkinson's Disease Rating Scale. Recent developments in Parkinson's disease, II 1987, 153-164. members of the UPDRS Development Committee, Florham Park, MacMillan Headcare Information. S. Fahn, C.D. Marsden, D.B. Calne, M. Goldstein (Eds.).
10. Fetoni V., Soliveri P., Monza D., Testa D., Girotti F. Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J. Neurol. Neurosurg. Psychiatry 1999, 66:541-544.
11. Gilman S., Wenning G.K., Low P.A., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
12. Habas C., Cabanis E.A. Cortical projection to the human red nucleus: complementary results with probabilistic tractography at 3 T. Neuroradiology 2007, 49:777-784.
13. Hedreen J.C. Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. J. Comp. Neurol. 1999, 409:400-410.
14. 18F]Fluoro-L-DOPA kinetics in positron emission tomography. J. Nucl. Med. 1992, 33:1472-1477.
15. Inoue M., Yagishita S., Ryo M., Hasegawa K., Amano N., Matsushita M. The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems. Acta Neuropathol. 1997, 93:585-591.
16. Juh R., Pae C.-U., Lee C.-U., et al. Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping. Neurosci. Res. 2005, 52:211-219.
17. 18F-DOPA PET study. Brain Res. 2003, 982:137-145.
18. 18F-dopa PET study. Neurobiol. Dis. 2008, 29:381-390.
19. Otsuka M., Ichiya Y., Kuwabara Y., et al. Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomography study. J. Neurol. Sci. 1996, 144:77-83.
20. Ozawa T., Paviour D., Quinn N.P., et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlation. Brain 2004, 127:2657-2671.
21. Patlak C.S., Blasberg R.G., Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 1983, 3:1-7.
22. Pavese N., Rivero-Bosch M., Lewis S.J., Whone A.L., Brooks D.J. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal (18)F-dopa PET study. Neuroimage 2011, 56:1463-1468.
23. Rakshi J.S., Uema T., Ito K., et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [18F]Dopa-PET study. Brain 1999, 122:1637-1650.
24. Samuels E.R., Szabadi E. Functional nauroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation. Curr. Neuropharmacol. 2008, 6:235-253.
25. 123I]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005, 128:1605-1612.
26. 123IBZM-SPECT. J. Neurol. Neurosurg. Psychiatry 1994, 57:1047-1056.
27. Spinks T.J., Jones T., Bloomfield P.M., et al. Physical characteristics of the ECAT EXACT3D positron tomography. Phys. Med. Biol. 2000, 45:2601-2618.
28. Taniwaki T., Nakagawa M., Yamada T., et al. Cerebral metabolic changes in early multiple system atrophy: a PET study. J. Neurol. Sci. 2002, 200:79-84.
29. Tsai A., Maehara K., Iizuka R. Loss of catecholaminergic neuron in the hypothalamus of multiple system atrophy. Rinsho Shinkeigaku 1992, 32:125-130.
30. 123I]β-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov. Disord. 2001, 16:1023-1032.
31. Wakabayashi K., Takahashi H. Cellular pathology in multiple system atrophy. Neuropathology 2006, 26:338-345.
32. Wenning G.K., Shlomo Y.B., Magalhães M., Daniel S.E., Quinn N.P. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994, 117:835-845.
33. Wenning G.K., Tison F., Ben-Shlomo Y., Daniel S.E., Quinn N.P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord. 1997, 12:133-147.
34. Wenning G.K., Stefanova N., Jellinger K.A., Poewe W., Schlossmacher M.G. Multiple system atrophy: a primary oligodendrogliopathy. Ann. Neurol. 2008, 64:239-246.
35. Whone A.L., Moore R.Y., Piccini P.P., Brooks D.J. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann. Neurol. 2003, 53:206-213.
36. 18F-Fluoro-L-DOPA PET data from a multicenter study. J. Nucl. Med. 2004, 45:1135-1145.
37. Yoshida M. Multiple system atrophy: α-synucelin and neuronal degeneration. Neuropathology 2007, 27:484-493.